TRANSFORMING GLAUCOMA SURGERIES
BRINGING VALUE TO ALL PARTNERS IN GLAUCOMA SURGERY
At LEP Biomedical, we aim to address the needs for all those involved in glaucoma drainage surgery.
​
"HyaGuard™" is our solution to post-operative inflammation and scarring in glaucoma drainage surgeries.
HyaGuard™ is rapidly inserted in the sub-conjunctival space where it delivers anti-inflammatory drugs in a controlled manner. This eliminates the need for self-administered drops, thus improving surgical success rates and improving patient quality of life.
FOR THE PATIENT
Our primary concern is your recovery.
​
HyaGuard™’s local action means drug delivery is guaranteed.
Anti-inflammatory drops will be eliminated, and patients can go about their daily lives.
HyaGuard™ is not externally visible once inserted and designed for your comfort.
FOR THE SURGEON
HyaGuard™ is rapidly inserted (<10 seconds) as part of a standard trabeculectomy.
​
HyaGuard™ is intended to reduce or eliminate the need for follow-up procedures. Glaucoma surgeries will become "one and done".
​
HyaGuard™ can be inserted without specialized applicators or reskilling.
​
FOR THE PAYER
HyaGuard™ is designed for use by all.
​
HyaGuard™ is intended to reduce outpatient hours and complications, thereby reducing the economic burden on hospitals and insurers.
HyaGuard™ is intended to ensure success for patients who may not be able to access more expensive drainage devices.
GLAUCOMA SURGERY IN NUMBERS
76
Million Diagnosed Glaucoma Patients Globally (2020)
112
Million Projected Global Glaucoma Patients by 2040
500k
Global Glaucoma Surgical Procedures (2022)
22-32%
Average Failure Rates for Glaucoma Drainage at Year 5
12-26%
Average Reoperation Rates for Drainage Surgeries by Year 5
OUR PARTNERS
